Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemia

Thrombosis and Haemostasis

Volumn 77, Issue 1, 1997, Pages 75-79

  De Maat, M P M ^a   Knipscheer, H C ^b   Kastelein, J J P ^b   Kluft, C ^a  

^a TNO   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CIPROFIBRATE; FIBRINOGEN; GEMFIBROZIL;

ACUTE PHASE RESPONSE; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; FIBRINOGEN BLOOD LEVEL; GENETIC POLYMORPHISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

EID: 0031042314     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1655910     Document Type: Article

References (37)

1. Meade TW, Brozovic M, Haines AP, Imenson JD, Mellows S, Miller GJ, North MRS, Stirling Y, Thompson SG. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-8.
2. Kannel WB, Wolf PA, Castelli WP, D'Agostino RBD. Fibrinogen and risk of cardiovascular disease: The Framingham Study. JAMA 1987; 258: 1183-6.
3. Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PRO-CAM Study in healthy men. Arterioscl Thromb 1994; 14: 54-9.
4. Stone MC, Thorp JM, Plasma fibrinogen: a major coronary risk factor. JR Coll Gen Pract 1985; 35: 565-9.
5. Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-5.
6. Yarnell JWG, Baker IA, Sweetnam PM, Bainton D, O'Brien JR, Whitehead PJ, Elwood PC. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation 1991; 83: 836-44.
7. Thompson SG, Kienast J, Pyke S, Haverkate F, van de Loo J, for the ECAT Angina Pectoris Study Group. Haemostatic risk factors and the risk for myocardial infarction or sudden cardiac death in patients with angina pectoris. N Engl J Med 1995; 332: 635-41.
8. Catapano AL. Mode of action of fibrates. Pharmac Res 1992; 26: 331-40.
9. Koenig W, Sund M, Ernst E, Mraz W, Doring A, Keil U, Hombach V. Blood viscosity and hyperlipoproteinemia. Biorheology 1989; 26: 601.
10. Lowe GDO, Drummond MN, Third JLH, Bremner WF, Forbes CD, Prentice CR, Lawrie TD. Increased plasma fibrinogen, and platelet aggregates in type II hyperlipoproteinaemia. Thromb Haemost 1979; 42: 1503-7.
11. Niort G, Bulgarelli A, Cassader M, Pagano G. Effect of short-term treatment with bezafibrate on plasma fibrinogen, fibrinopeptide A, platelet activation and blood filterability in atherosclerotic hyperfibrinogenemic patients. Atherosclerosis 1988; 71: 113.
12. Bo M, Bonino F, Neirotti M, Gottero M, Pernigotti L, Molaschi M, Fabris F. Hemorheologic and coagulative pattern in hypercholesterolemic subjects treated with lipid-lowering drugs. Angiology 1991; 42: 106.
13. Branchi A, Rovellini A, Sommariva D, Gugliandolo AG, Fasoli A. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia. Thromb Haemost 1993; 70: 241-3.
14. Aimer LO, Kjelström T. The fibrinolytic system and coagulation during bezafibrate treatment of hypertriglyceridemia. Atherosclerosis 1986; 61: 81-5.
15. Caimi G, francavilla g, Romano A, Catania A, Santonocito G, Sarno A. Blood rheology changes during bezafibrate treatment. Br J Clin Practice 1988; 42: 456-8.
16. Simpson IA, Lorimer AR, Walker ID, Davidson JF. Effect of ciprofibrate on platelet aggregation and fibrinolysis in patients with hypercholesterolaemia. Thromb Haemost 1985; 54: 442-4.
17. Andersen P, Smith P, Seljeflot I, Brataker S, Arnesen H. Effects of gemfibrozil on lipids and haemostasis after myocardial infarction. Thromb Haemost 1990; 63: 174-7.
18. O'Brien J, Etherington MD, Shuttleworth R, Adams C, Middleton JE et al. A pilot study of the effect of gemfibrozil on some haematological parameters. Thromb Res 1982; 26: 275-9.
19. Avellone G, Di Garbo V, Crodova R, Ranelli G, De Simone R, Bimppiani G. Effect of gemfibrozil treatment on fibrinolysis system in patients with hypertriglyceridemia. Curr Therapeutic Res 1992; 52: 338-48.
20. 1+2 concentration, a marker of coagulability, in patients with coronary heart disease. Thromb Haemost 1992; 67: 503-6.
21. Kushner I. The phenomenon of the acute phase response. Ann N Y Acad Sci 1982; 389: 39-48.
22. Baumann H, Onorato V, Gauldie J, Jahreis GP. Distinct sets of acute phase plasma proteins are stimulated by separate human hepatocyte-stimulating factors in monokines in rat hepatoma cells. J Biol Chem 1987; 262: 9756-68.
23. Pickart L. Suppression of acute-phase synthesis of fibrinogen by a hypolipidemic drug (Clofibrate). Int J Tiss Reac 1981; 3: 65-72.
24. Humphries SE, Cook M, Dubowitz M, Stirling Y, Meade TW. Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrations. Lancet 1987; i: 1452-5.
25. +1689 (AvaII), and BclI (β-fibrinogen) and TaqI (α-fibrinogen), and their detection by PCR. Human Mutation 1994; 3: 79-81.
26. Cook M, Godiner N, Green F, Stirling Y, Meade TW, Humphries SE. Genetic control of plasma fibrinogen levels. In: Fibrinogen 3. Biochemistry, biological functions, gene regulations and expression. Mosseson MW, Amran DL, Siebenlist KR, DiOrio JP, eds. Amsterdam: Elsevier Science Publishers BV, 1988: 11-5.
27. Thomas AE, Green FR, Kelleher CH, Wilkes HC, Brennan PJ, Meade TW, Humphries SE. Variation in the promoter region of the β-fibrinogen gene is associated with plasma fibrinogen levels in smokers and non-smokers. Thromb Haemost 1991; 65: 487-90.
28. Green F. Hamsten A, Blombäck M, Humphries S. The role of β-fibrinogen genotype in determining plasma levels in young survivors of myocardial infarction and healthy controls from Sweden. Thromb Haemost 1993; 70: 915-20.
29. de Bart ACW, de Maat MPM, Hennis BC, Kluft C. Longitudinal stability of plasma fibrinogen levels in healthy volunteers. In: Fibrinogen: a "new" cardiovascular risk factor. Ernst E, Koenig W, Lowe GDO, Meade TW, eds. Vienna, Blackwell-MZV, 1992: 86-90.
30. Von Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-46.
31. Knipscheer HC, de Valois JC, van den Ende A, ten Cate JW, Kastelein JJP. Ciprofibrate versus Gemfibrozil in the treatment of primary hyperlipidemia. Atherosclerosis 1996; 124 Suppl: S75-S81.
32. de Maat MPM, Pietersma A, Kofflard M, Sluiter W, Kluft C. The complex association of plasma fibrinogen levels with coronary artery disease, smoking and inflammatory markers. Atherosclerosis 1996; 121: 185-91.
33. Cortellaro M, Boschetti C, Cofrancesco E, Zanussi C, Catalano M, de Gaetano G, Gabrielli L, Lombardi B, Specchia G, Tavazzi L, Tremoli E, Della Volpe A, Polli E, PLAT Study Group. The PLAT Study: a multidisciplinary study of hemostatic function and conventional risk factors in vascular disease patients. Atherosclerosis 1991; 90: 109-18.
34. Fowkes FGR, Connor JM, Smith FB, Wood J, Donnan PT, Lowe GDO. Fibrinogen genotype and risk of peripheral atherosclerosis. Lancet 1992; 339: 693-6.
35. Wiseman SA, Jaye PD, Powell JT, Humphries SE, Greenhalgh RM. Frequency of DNA polymorphisms of the apolipoprotein B and fibrinogen genes in young patients with peripheral arterial disease. In: Applied Cardiovascular Biology 1989. Zilla P, Fasol R, Callow A, eds. Int Soc Appl Cardiovasc Biol Basel, Karger 1990, vol 1, pp 118-23.
36. Scarabin PY, Bara L, Ricard S, Poirier O, Cambou JP, Arveiler D, Luc G, Evans AE, Samama MM, Cambien F. Genetic variation at the β-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocardial infarction. The ECTIM study. Arterioscl Thrombos 1993; 13: 886-91.
37. Koster T, Rosendaal FR, Reitsma PH, van der Velden PA, Briët E, Vandenbroucke JP. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms - the Leiden thrombophilia Study (LETS). Thromb Haemost 1994; 71: 719-22.